# Title

 Food and Drugs. PART 807â€”ESTABLISHMENT REGISTRATION AND DEVICE LISTING FOR MANUFACTURERS AND INITIAL IMPORTERS OF DEVICES


# ID

 CFR-2018-title21-vol8.Pt. 807


# Structured Analysis Summary

| Type        | Values                                                                                                                                                                                                           |
|:------------|:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Constraints | ['before', 'within', 'more than', 'after', 'at least', 'prior to']                                                                                                                                               |
| Duration    | ['30.0 day', '3.0 year', '10.0 day', '90.0 day']                                                                                                                                                                 |
| Condition   | ['until', 'not subject to', 'unless', 'where', 'if not', 'subject to', 'when', 'if']                                                                                                                             |
| Entities    | ['United States', 'Additional', 'Public', 'Annual', 'G112', 'New Drug Application', 'Food', 'English', 'Rm', 'Research', 'Beltsville, MD', 'Data', 'G609', 'Safety', 'Failure', 'Humanitarian Device Exemption'] |
| Date        | ['2018-12-31', '1990-12-01', '1978-10-10', '1976-05-28', '2018-10-01', '2018-09-30']                                                                                                                             |


# Structured Analysis With Context

 


## Constraints

| Constraints   | Context                                                                                                                                 |
|:--------------|:----------------------------------------------------------------------------------------------------------------------------------------|
| within        | or interplant transfer of a device between establishments within the same parent, subsidiary, and/or affiliate company; (2)             |
| before        | (3) Any distribution of a device,  before the effective date of part 812 of this                                                        |
| before        | (3) Any distribution of a device,  before the effective date of part 812 of this                                                        |
| within        | regarding safety and effectiveness will be made available within 30 days of request by any person if                                    |
| more than     | of these organizations when operations are conducted at more than one establishment and there exists joint ownership and                |
| within        | or determination that a product is a device within the meaning of section 201(h) of the Federal                                         |
| within        | into an operation described in &#167;&#8201;807.20(a) shall register within 30 days after entering into such an operation               |
| after         | described in &#167;&#8201;807.20(a) shall register within 30 days after entering into such an operation and submit device               |
| within        | information as described in &#167;&#8201;807.25(b) shall be made within 30 days of any change to such information;                      |
| prior to      | and approval or which was in commercial distribution prior to  May 28, 1976.                                                            |
| after         | the date of initial listing, and in use after October 10, 1978, but before the date of                                                  |
| before        | and in use after October 10, 1978, but before the date of initial listing, as follows: (1)                                              |
| after         | which a material change has been made anytime after  initial listing.                                                                   |
| after         | and advertisements from the historical file 3 years after the date of the last shipment of a                                            |
| more than     | the historical file may be physically located in more than  one place in the establishment or in                                        |
| more than     | the historical file may be physically located in more than  one place in the establishment or in                                        |
| before        | device listings for foreign establishments must be submitted before the device may be imported or offered for                           |
| after         | will assign each device establishment a registration number after verifying the initial establishment registration information that has |
| within        | Administration district offices the same information for firms within  the geographical area of such district offices.                  |
| within        | (a) Any establishment  within any foreign country engaged in the manufacture, preparation,                                              |
| within        | agent's name, address, or phone number to FDA within  10-business days of the change.                                                   |
| at least      | notification submission to the Food and Drug Administration at least 90 days before he proposes to begin the                            |
| before        | Food and Drug Administration at least 90 days before he proposes to begin the introduction or delivery                                  |
| before        | Food and Drug Administration at least 90 days before he proposes to begin the introduction or delivery                                  |
| after         | or (ii) a device introduced for commercial distribution after May 28, 1976, that has subsequently been reclassified                     |
| before        | under section 513(f)(2) of the act, is pending before  the Food and Drug Administration.                                                |
| within        | requirements of this subpart if the device is within the meaning of section 520(b) of the Federal                                       |
| before        | if: (1) The device was in commercial distribution before May 28, 1976; or (2) A premarket notification                                  |
| before        | for introduction into interstate commerce for commercial distribution before December 1, 1990; and (2) For which no                     |
| at least      | a new premarket notification containing the requested information at least 90 days before the owner or operator intends                 |
| before        | containing the requested information at least 90 days before the owner or operator intends to market the                                |
| within        | If the additional information is not submitted  within 30 days following the date of the request,                                       |
| prior to      | equivalence is a device that was legally marketed prior to May 28, 1976, or a device which has                                          |
| after         | the existence of the submission until 90 days after the Food and Drug Administration's receipt of a                                     |
| within        | safety and effectiveness data available to the public within 30 days of the issuance of a determination                                 |
| after         | notification submission cannot be granted beyond 30 days after  FDA issues a determination of equivalency.                              |
| before        | substantially equivalent to a device in commercial distribution before May 28, 1976, or is substantially equivalent to                  |
| after         | equivalent to a device introduced into commercial distribution after May 28, 1976, that has subsequently been reclassified              |
| after         | to FDA under part 54 of this chapter. after                                                                                             |


## Duration

| Duration   | Context                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|:-----------|:-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 30.0 day   | (p) 510(k) statement means a statement, made under section 513(i) of the act, asserting that all information in a premarket notification submission regarding safety and effectiveness will be made available within 30 days of request by any person if the device described in the premarket notification submission is determined to be substantially equivalent.                                                                                                                                                                 |
| 30.0 day   | An owner or operator of an establishment who has not previously entered into an operation described in &#167;&#8201;807.20(a) shall register within 30 days after entering into such an operation and submit device listing information at that time.                                                                                                                                                                                                                                                                                |
| 30.0 day   | Annual registration shall take place during the period beginning on October 1 and ending on December 31 of each fiscal year;                                                                                                                                                                                                                                                                                                                                                                                                         |
|            |               (2) Updates to the registration information as described in &#167;&#8201;807.25(b) shall be made within 30 days of any change to such information;                                                                                                                                                                                                                                                                                                                                                                     |
|            |               (3) Every fiscal year, during the period beginning on October 1 and ending on December 31, owners or operators shall review and update all of their device listing information that is on file at FDA, reporting any changes or deletions to listings and any new listings that were not previously reported.                                                                                                                                                                                                          |
| 3.0 year   | (c) Each owner or operator may discard labeling and advertisements from the historical file 3 years after the date of the last shipment of a discontinued device by an owner or operator.                                                                                                                                                                                                                                                                                                                                            |
| 10.0 day   | (3) The foreign establishment or the United States agent shall report changes in the United States agent's name, address, or phone number to FDA within 10-business days of the change.                                                                                                                                                                                                                                                                                                                                              |
| 90.0 day   | (a) Except as provided in paragraph (b) of this section, each person who is required to register his establishment pursuant to &#167;&#8201;807.20 must submit a premarket notification submission to the Food and Drug Administration at least 90 days before he proposes to begin the introduction or delivery for introduction into interstate commerce for commercial distribution of a device intended for human use which meets any of the following criteria:                                                                 |
|            |               (1) The device is being introduced into commercial distribution for the first time; that is, the device is not of the same type as, or is not substantially equivalent to, (i) a device in commercial distribution before May 28, 1976, or (ii) a device introduced for commercial distribution after May 28, 1976, that has subsequently been reclassified into class I or II.                                                                                                                                        |
| 90.0 day   | A request for additional information will advise the owner or operator that there is insufficient information contained in the original premarket notification submission for the Commissioner to make this determination and that the owner or operator may either submit the requested data or a new premarket notification containing the requested information at least 90 days before the owner or operator intends to market the device, or submit a premarket approval application in accordance with section 515 of the act. |
| 30.0 day   | If the additional information is not submitted within 30 days following the date of the request, the Commissioner will consider the premarket notification to be withdrawn.                                                                                                                                                                                                                                                                                                                                                          |
| 90.0 day   | (b) The Food and Drug Administration will not disclose publicly the existence of a premarket notification submission for a device that is not on the market and where the intent to market the device has not been disclosed for 90 days from the date of receipt of the submission, if:                                                                                                                                                                                                                                             |
|            |               (1) The person submitting the premarket notification submission requests in the submission that the Food and Drug Administration hold as confidential commercial information the intent to market the device and submits a written certification to the Commissioner:                                                                                                                                                                                                                                                  |
|            |               (i) That the person considers his intent to market the device to be confidential commercial information;                                                                                                                                                                                                                                                                                                                                                                                                               |
|            |               (ii) That neither the person nor, to the best of his knowledge, anyone else, has disclosed through advertising or any other manner, his intent to market the device to scientists, market analysts, exporters, or other individuals, except employees of, or paid consultants to, the establishment or individuals in an advertising or law firm pursuant to commercial arrangements with appropriate safeguards for secrecy;                                                                                          |
|            |               (iii) That the person will immediately notify the Food and Drug Administration if he discloses the intent to market the device to anyone, except employees of, or paid consultants to, the establishment or individuals in an advertising or law firm pursuant to commercial arrangements with appropriate safeguards for secrecy;                                                                                                                                                                                     |
|            |               (iv) That the person has taken precautions to protect the confidentiality of the intent to market the device; and                                                                                                                                                                                                                                                                                                                                                                                                      |
|            |               (v) That the person understands that the submission to the government of false information is prohibited by 18 U.S.C. 1001 and 21 U.S.C. 331(q); and                                                                                                                                                                                                                                                                                                                                                                   |
|            |               (2) The Commissioner agrees that the intent to market the device is confidential commercial information.                                                                                                                                                                                                                                                                                                                                                                                                               |
| 90.0 day   | (c) Where the Commissioner determines that the person has complied with the procedures described in paragraph (b) of this section with respect to a device that is not on the market and where the intent to market the device has not been disclosed, and the Commissioner agrees that the intent to market the device is confidential commercial information, the Commissioner will not disclose the existence of the submission for 90 days from the date of its receipt by the agency.                                           |
| 90.0 day   | (1) The Commissioner requests in writing additional information regarding the device pursuant to &#167;&#8201;807.87(h), in which case the Commissioner will not disclose the existence of the submission until 90 days after the Food and Drug Administration's receipt of a complete premarket notification submission;                                                                                                                                                                                                            |
|            |               (2) The Commissioner determines that the device intended to be introduced is a class III device and cannot be marketed without premarket approval or reclassification, in which case the Commissioner will not disclose the existence of the submission unless a petition for reclassification is submitted under section 513(f)(2) of the act and its existence can be disclosed under &#167;&#8201;860.5(d) of this chapter; or                                                                                      |
|            |               (d) FDA will make a 510(k) summary of the safety and effectiveness data available to the public within 30 days of the issuance of a determination that the device is substantially equivalent to another device.                                                                                                                                                                                                                                                                                                       |
| 30.0 day   | (1) The Commissioner requests in writing additional information regarding the device pursuant to &#167;&#8201;807.87(h), in which case the Commissioner will not disclose the existence of the submission until 90 days after the Food and Drug Administration's receipt of a complete premarket notification submission;                                                                                                                                                                                                            |
|            |               (2) The Commissioner determines that the device intended to be introduced is a class III device and cannot be marketed without premarket approval or reclassification, in which case the Commissioner will not disclose the existence of the submission unless a petition for reclassification is submitted under section 513(f)(2) of the act and its existence can be disclosed under &#167;&#8201;860.5(d) of this chapter; or                                                                                      |
|            |               (d) FDA will make a 510(k) summary of the safety and effectiveness data available to the public within 30 days of the issuance of a determination that the device is substantially equivalent to another device.                                                                                                                                                                                                                                                                                                       |
| 30.0 day   | Accordingly, even when a 510(k) submitter has complied with the conditions set forth in paragraphs (b) and (c) of this section, confidentiality for a premarket notification submission cannot be granted beyond 30 days after FDA issues a determination of equivalency.                                                                                                                                                                                                                                                            |


## Condition

| Condition      | Context                                                                                                                                         |
|:---------------|:------------------------------------------------------------------------------------------------------------------------------------------------|
| where          | labeling, changes in lot number, and, for devices where the biological activity or known composition differs with                               |
| if             | asserting that all information in a premarket not if ication submission regarding safety and effectiveness will be                              |
| where          | mailboxes, answering machines or services, or other places where an individual acting as the foreign establishment's agent                      |
| if not         | that is an owner, consignee, or recipient, even if not the initial owner, consignee, or recipient, of the                                       |
| unless         | who ultimately purchases, receives, or uses the device, unless the foreign establishment ships the device directly to                           |
| when           | under the control of one of these organizations when operations are conducted at more than one establishment                                    |
| not subject to | diagnostic products and in vitro diagnostic biological products not subject to licensing under section 351 of the Public Health                 |
| when           | Initial importers shall also be prepared to submit,  when requested by FDA, the proprietary name, if any,                                       |
| if             | submit, when requested by FDA, the proprietary name, if any, and the common or usual name of                                                    |
| subject to     | (a) Owners or operators of establishments that are  subject to the registration and listing requirements of this part                           |
| if             | be submitted electronically, a waiver may be requested. if                                                                                      |
| if             | Waivers will be granted only  if use of electronic means is not reasonable for                                                                  |
| if             | an initial importer as defined in &#167;&#8201;807.3(g) and, if so, whether it also conducts any other activities                               |
| when           | the FDA electronic device registration and listing system. when                                                                                 |
| when           | also be made at other times, such as when  a device is introduced into commercial distribution,                                                 |
| when           | also be made at other times, such as when  a device is introduced into commercial distribution,                                                 |
| when           | also be made at other times, such as when  a device is introduced into commercial distribution,                                                 |
| until          | may not appear on the FDA Web site until such time as the owner or operator submits                                                             |
| subject to     | (a) All owners or operators that are  subject to the registration and listing requirements of this part                                         |
| unless         | the FDA electronic device registration and listing system, unless granted a waiver from electronic submission in accordance                     |
| if             | the Web site address of the device establishment, if any; the name, address, phone number, fax number,                                          |
| unless         | with all required registration and listing information electronically unless a waiver from electronic submission has been granted               |
| when           | from FDA concerning registration and listing; (3) Supplying, when requested by FDA, the names of all officers,                                  |
| if             | from FDA by email, or by postal mail if the owner or operator has been granted a                                                                |
| unless         | listing information must be submitted to FDA electronically unless a waiver from electronic submission has been granted                         |
| where          | ownership and control of the owner or operator where the device is manufactured, repackaged, relabeled, or otherwise                            |
| where          | ownership and control of the owner or operator where the device is manufactured, repackaged, relabeled, or otherwise                            |
| subject to     | device exemption for each device listed that is subject to sections 505, 510(k), 513(f)(2), 515, or 520(m) of                                   |
| subject to     | initial listing, as follows: (1) For each device subject to section 514 or 515 of the act that                                                  |
| subject to     | For each device that is neither restricted nor subject to section 514 or 515 of the act, a                                                      |
| if             | fulfills the requirements of this section, but only if the labeling and advertisements are retrievable in a                                     |
| subject to     | request, the following information: (1) For a device subject to section 514 or 515 of the act that                                              |
| where          | A request for all advertisements will,  where feasible, be accompanied by an explanation of the                                                 |
| subject to     | device that is neither a restricted device, nor subject to section 514 of 515 of the act, the                                                   |
| not subject to | the registrant has determined that the device is not subject to  section 514 or 515 of the act.                                                 |
| if             | (a) Updating of device listing information is required  if an additional establishment begins to engage in any                                  |
| if             | Updating of the listing is also required  if an establishment begins performing another activity on or                                          |
| if             | introducing into commercial distribution an exempt device ident if ied with a product code that is not                                          |
| if             | introducing into commercial distribution an exempt device ident if ied with a product code that is not                                          |
| if             | using the electronic device registration and listing system. if                                                                                 |
| when           | listing information described in &#167;&#167;&#8201;807.22, 807.25, (and &#167;&#8201;807.26 when such information is requested by FDA), at the |
| until          | may not appear on the FDA Web site until the required information is submitted to and processed                                                 |
| if             | official correspondent by email, or by postal mail if the owner or operator has been granted a                                                  |
| subject to     | 351 of the Public Health Service Act, are subject to part 607 of this chapter; registration and listing                                         |
| subject to     | 351 of the Public Health Service Act, are subject to part 607 of this chapter; registration and listing                                         |
| if             | is marketed and the FDA-assigned premarket submission number, if this information would reveal a confidential business relationship;            |
| unless         | or offered for import into the United States unless it is the subject of a device listing                                                       |
| if             | and fax numbers, email address, and registration number, if any has been assigned, of any importer (defined                                     |
| if             | and fax numbers, email address, and registration number, if any has been assigned, of each person who                                           |
| if             | A custom device is exempt from premarket not if ication requirements of this subpart                                                            |
| if             | (b) The establishment registration number,  if applicable, of the owner or operator submitting the                                              |
| if             | put under section 513 of the act and, if  known, its appropriate panel; or,                                                                     |
| if             | put under section 513 of the act and, if  known, its appropriate panel; or,                                                                     |
| where          | on the safety and effectiveness of the device. where                                                                                            |
| if             | regulations in part 812 of this chapter, or if the investigation was not conducted in compliance with                                           |
| not subject to | in part 56 of this chapter, or was not subject to the regulations under &#167;&#8201;56.104 or &#167;&#8201;56.105, and the                     |
| if             | regulations in part 812 of this chapter, or if the investigation was not conducted in compliance with                                           |
| if             | the requirements under &#167;&#8201;812.28 of this chapter apply. if                                                                            |
| where          | (b) Be bound into a volume or volumes,  where  necessary.                                                                                       |
| until          | will accept summaries as well as amendments thereto until such time as FDA issues a determination of                                            |
| if             | the device, including the trade or proprietary name if applicable, the common or usual name, and the                                            |
| if             | the device, including the trade or proprietary name if applicable, the common or usual name, and the                                            |
| where          | treat, prevent, cure, or mitigate, including a description, where appropriate, of the patient population for which the                          |
| when           | affect the safety and effectiveness of the device when used as labeled; and (6) If the device                                                   |
| if             | If the indication statements are d if ferent from those of the legally marketed device                                                          |
| where          | This discussion shall include,  where applicable, a description of the subjects upon whom                                                       |
| where          | the device has not been so disclosed, except where the submission is subject to an exception under                                              |
| where          | the device has not been so disclosed, except where the submission is subject to an exception under                                              |
| where          | the device has not been so disclosed, except where the submission is subject to an exception under                                              |
| where          | the device has not been so disclosed, except where the submission is subject to an exception under                                              |
| subject to     | been so disclosed, except where the submission is subject to an exception under paragraph (b) or (c) of                                         |
| where          | device that is not on the market and where the intent to market the device has not                                                              |
| if             | disclose publicly the existence of a premarket not if ication submission for a device that is not                                               |
| where          | device that is not on the market and where the intent to market the device has not                                                              |
| where          | device that is not on the market and where the intent to market the device has not                                                              |
| when           | submission for the device for an additional time when  any of the following occurs:                                                             |
| until          | will not disclose the existence of the submission until 90 days after the Food and Drug Administration's                                        |
| unless         | will not disclose the existence of the submission unless a petition for reclassification is submitted under section                             |
| when           | Accordingly, even  when a 510(k) submitter has complied with the conditions                                                                     |
| when           | for disclosure by the Food and Drug Administration when the intent to market the device is no                                                   |
| unless         | no longer confidential in accordance with this section, unless exempt from public disclosure in accordance with part                            |
| unless         | to the public shall be retained as confidential unless such data and information become available for release                                   |
| until          | Request additional information; or (4) Withhold the decision until a certification or disclosure statement is submitted to                      |
| if             | predicate device and contains information, including clinical data if deemed necessary by the Commissioner, that demonstrates that              |


## Entities

| Entities                      | Context                                                                                                                                                            |
|:------------------------------|:-------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Food                          | Food  and Drugs.                                                                                                                                                   |
| United States                 | neither imported nor offered for import into the United States .                                                                                                   |
| Safety                        | Safety and effectiveness information refers to safety and effectiveness                                                                                            |
| United States                 | (s)  United States agent means a person residing or maintaining a                                                                                                  |
| United States                 | (s)  United States agent means a person residing or maintaining a                                                                                                  |
| Humanitarian Device Exemption | submission, such as a Premarket Approval Application (PMA); Humanitarian Device Exemption (HDE); New Drug Application (NDA); Biologics License Application         |
| New Drug Application          | Premarket Approval Application (PMA); Humanitarian Device Exemption (HDE); New Drug Application (NDA); Biologics License Application (BLA); de novo classification |
| United States                 | this part, a company or individual in the United States that is an owner, consignee, or recipient, even                                                            |
| United States                 | this part, a company or individual in the United States that is an owner, consignee, or recipient, even                                                            |
| United States                 | facilitate the import of its device into the United States .                                                                                                       |
| Annual                        | Annual registration shall take place during the period beginning                                                                                                   |
| Failure                       | Failure to submit any of the required information on                                                                                                               |
| Additional                    | Additional  listing information.                                                                                                                                   |
| United States                 | be imported or offered for import into the United States .                                                                                                         |
| Public                        | Public  availability of establishment registration and device listing information.                                                                                 |
| United States                 | importing or offering for import devices into the United States .                                                                                                  |
| United States                 | is imported or offered for import into the United States shall register such establishment and list such devices                                                   |
| United States                 | the name, address, and phone number of its United States agent as part of its initial and updated                                                                  |
| United States                 | Each foreign establishment shall designate only one  United States  agent and may designate the                                                                    |
| United States                 | Each foreign establishment shall designate only one  United States  agent and may designate the                                                                    |
| United States                 | (1) The  United States agent shall reside or maintain a place of                                                                                                   |
| United States                 | (1) The  United States agent shall reside or maintain a place of                                                                                                   |
| United States                 | (2) Upon request from FDA, the  United States agent shall assist FDA in communications with the                                                                    |
| United States                 | (2) Upon request from FDA, the  United States agent shall assist FDA in communications with the                                                                    |
| United States                 | FDA may provide information or documents to the United States agent, and such an action shall be considered                                                        |
| United States                 | (3) The foreign establishment or the  United States  agent shall report changes in the                                                                             |
| United States                 | (3) The foreign establishment or the  United States  agent shall report changes in the                                                                             |
| United States                 | be imported or offered for import into the United States unless it is the subject of a device                                                                      |
| English                       | and device listing information shall be in the English  language.                                                                                                  |
| United States                 | offers for import the establishment's devices into the United States .                                                                                             |
| United States                 | facilitate the import of its device into the United States .                                                                                                       |
| Food                          | of the act, or because the Commissioner of Food and Drugs has found, under section 510(g)(5) of                                                                    |
| United States                 | data are from clinical investigations conducted in the United States , a statement that each investigation was conducted                                           |
| United States                 | data are from clinical investigations conducted outside the United States , the requirements under &#167;&#8201;812.28 of this chapter                             |
| G609                          | G609 , Silver Spring, MD 20993-0002.                                                                                                                               |
| Research                      | regulated by the Center for Biologics Evaluation and Research , be addressed to the Food and Drug                                                                  |
| Research                      | regulated by the Center for Biologics Evaluation and Research , be addressed to the Food and Drug                                                                  |
| Rm                            | 71,  Rm .                                                                                                                                                          |
| G112                          | G112 , Silver Spring, MD 20993-0002; or for devices                                                                                                                |
| Research                      | regulated by the Center for Drug Evaluation and Research , be addressed to the Central Document Room,                                                              |
| Research                      | regulated by the Center for Drug Evaluation and Research , be addressed to the Central Document Room,                                                              |
| Beltsville, MD                | Research, Food and Drug Administration, 5901-B Ammendale Rd., Beltsville, MD  20705-1266.                                                                          |
| Data                          | Data and information relating to safety and effectiveness of                                                                                                       |
| Food                          | market at the initiative of the Commissioner of Food and Drugs or has not been determined to                                                                       |


## Date

| Date       | Context                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|:-----------|:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1976-05-28 | (3) Any distribution of a device, before the effective date of part 812 of this chapter, that was not introduced or delivered for introduction into interstate commerce for commercial distribution before May 28, 1976, and that is classified into class III under section 513(f) of the act: Provided, That the device is intended solely for investigational use, and under section 501(f)(2)(A) of the act the device is not required to have an approved premarket approval application as provided in section 515 of the act; or |
|            |               (4) For foreign establishments, the distribution of any device that is neither imported nor offered for import into the United States.                                                                                                                                                                                                                                                                                                                                                                                    |
| 2018-10-01 | (u) Fiscal year means the FDA fiscal year, which runs from October 1 through September 30.                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| 2018-09-30 | (u) Fiscal year means the FDA fiscal year, which runs from October 1 through September 30.                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| 2018-10-01 | Annual registration shall take place during the period beginning on October 1 and ending on December 31 of each fiscal year;                                                                                                                                                                                                                                                                                                                                                                                                            |
|            |               (2) Updates to the registration information as described in &#167;&#8201;807.25(b) shall be made within 30 days of any change to such information;                                                                                                                                                                                                                                                                                                                                                                        |
|            |               (3) Every fiscal year, during the period beginning on October 1 and ending on December 31, owners or operators shall review and update all of their device listing information that is on file at FDA, reporting any changes or deletions to listings and any new listings that were not previously reported.                                                                                                                                                                                                             |
| 2018-12-31 | Annual registration shall take place during the period beginning on October 1 and ending on December 31 of each fiscal year;                                                                                                                                                                                                                                                                                                                                                                                                            |
|            |               (2) Updates to the registration information as described in &#167;&#8201;807.25(b) shall be made within 30 days of any change to such information;                                                                                                                                                                                                                                                                                                                                                                        |
|            |               (3) Every fiscal year, during the period beginning on October 1 and ending on December 31, owners or operators shall review and update all of their device listing information that is on file at FDA, reporting any changes or deletions to listings and any new listings that were not previously reported.                                                                                                                                                                                                             |
| 2018-10-01 | Annual registration shall take place during the period beginning on October 1 and ending on December 31 of each fiscal year;                                                                                                                                                                                                                                                                                                                                                                                                            |
|            |               (2) Updates to the registration information as described in &#167;&#8201;807.25(b) shall be made within 30 days of any change to such information;                                                                                                                                                                                                                                                                                                                                                                        |
|            |               (3) Every fiscal year, during the period beginning on October 1 and ending on December 31, owners or operators shall review and update all of their device listing information that is on file at FDA, reporting any changes or deletions to listings and any new listings that were not previously reported.                                                                                                                                                                                                             |
| 2018-12-31 | Annual registration shall take place during the period beginning on October 1 and ending on December 31 of each fiscal year;                                                                                                                                                                                                                                                                                                                                                                                                            |
|            |               (2) Updates to the registration information as described in &#167;&#8201;807.25(b) shall be made within 30 days of any change to such information;                                                                                                                                                                                                                                                                                                                                                                        |
|            |               (3) Every fiscal year, during the period beginning on October 1 and ending on December 31, owners or operators shall review and update all of their device listing information that is on file at FDA, reporting any changes or deletions to listings and any new listings that were not previously reported.                                                                                                                                                                                                             |
| 1976-05-28 | (2) The product code for each device that is exempt from premarket notification and approval or which was in commercial distribution prior to May 28, 1976.                                                                                                                                                                                                                                                                                                                                                                             |
| 1978-10-10 | (a) Each owner or operator shall maintain a historical file containing the labeling and advertisements in use on the date of initial listing, and in use after October 10, 1978, but before the date of initial listing, as follows:                                                                                                                                                                                                                                                                                                    |
|            |               (1) For each device subject to section 514 or 515 of the act that is not a restricted device, a copy of all labeling for the device;                                                                                                                                                                                                                                                                                                                                                                                      |
|            |               (2) For each restricted device, a copy of all labeling and advertisements for the device;                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| 2018-10-01 | (b) As specified in &#167;&#8201;807.22(b)(1) and (b)(3), all owners or operators shall update their establishment registration and device listings annually during the period beginning on October 1 and ending on December 31 of each fiscal year.                                                                                                                                                                                                                                                                                    |
| 2018-12-31 | (b) As specified in &#167;&#8201;807.22(b)(1) and (b)(3), all owners or operators shall update their establishment registration and device listings annually during the period beginning on October 1 and ending on December 31 of each fiscal year.                                                                                                                                                                                                                                                                                    |
| 1976-05-28 | (a) Except as provided in paragraph (b) of this section, each person who is required to register his establishment pursuant to &#167;&#8201;807.20 must submit a premarket notification submission to the Food and Drug Administration at least 90 days before he proposes to begin the introduction or delivery for introduction into interstate commerce for commercial distribution of a device intended for human use which meets any of the following criteria:                                                                    |
|            |               (1) The device is being introduced into commercial distribution for the first time; that is, the device is not of the same type as, or is not substantially equivalent to, (i) a device in commercial distribution before May 28, 1976, or (ii) a device introduced for commercial distribution after May 28, 1976, that has subsequently been reclassified into class I or II.                                                                                                                                           |
| 1976-05-28 | (a) Except as provided in paragraph (b) of this section, each person who is required to register his establishment pursuant to &#167;&#8201;807.20 must submit a premarket notification submission to the Food and Drug Administration at least 90 days before he proposes to begin the introduction or delivery for introduction into interstate commerce for commercial distribution of a device intended for human use which meets any of the following criteria:                                                                    |
|            |               (1) The device is being introduced into commercial distribution for the first time; that is, the device is not of the same type as, or is not substantially equivalent to, (i) a device in commercial distribution before May 28, 1976, or (ii) a device introduced for commercial distribution after May 28, 1976, that has subsequently been reclassified into class I or II.                                                                                                                                           |
| 1976-05-28 | (b) A distributor who places a device into commercial distribution for the first time under his own name and a repackager who places his own name on a device and does not change any other labeling or otherwise affect the device shall be exempted from the premarket notification requirements of this subpart if:                                                                                                                                                                                                                  |
|            |               (1) The device was in commercial distribution before May 28, 1976; or                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|            |               (2) A premarket notification submission was filed by another person.                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| 1990-12-01 | (k) For submissions claiming substantial equivalence to a device which has been classified into class III under section 513(b) of the act:                                                                                                                                                                                                                                                                                                                                                                                              |
|            |               (1) Which was introduced or delivered for introduction into interstate commerce for commercial distribution before December 1, 1990; and                                                                                                                                                                                                                                                                                                                                                                                  |
|            |               (2) For which no final regulation requiring premarket approval has been issued under section 515(b) of the act, a summary of the types of safety and effectiveness problems associated with the type of devices being compared and a citation to the information upon which the summary is based (class III summary).                                                                                                                                                                                                     |
| 1976-05-28 | A legally marketed device to which a new device may be compared for a determination regarding substantial equivalence is a device that was legally marketed prior to May 28, 1976, or a device which has been reclassified from class III to class II or I (the predicate), or a device which has been found to be substantially equivalent through the 510(k) premarket notification process;                                                                                                                                          |
|            |               (4) A description of the device that is the subject of the premarket notification submission, such as might be found in the labeling or promotional material for the device, including an explanation of how the device functions, the scientific concepts that form the basis for the device, and the significant physical and performance characteristics of the device, such as device design, material used, and physical properties;                                                                                 |
| 1976-05-28 | Submission of a premarket notification in accordance with this subpart, and a subsequent determination by the Commissioner that the device intended for introduction into commercial distribution is substantially equivalent to a device in commercial distribution before May 28, 1976, or is substantially equivalent to a device introduced into commercial distribution after May 28, 1976, that has subsequently been reclassified into class I or II, does not in any way denote official approval of the device.                |
| 1976-05-28 | Submission of a premarket notification in accordance with this subpart, and a subsequent determination by the Commissioner that the device intended for introduction into commercial distribution is substantially equivalent to a device in commercial distribution before May 28, 1976, or is substantially equivalent to a device introduced into commercial distribution after May 28, 1976, that has subsequently been reclassified into class I or II, does not in any way denote official approval of the device.                |


